Dkk3 levels in patients with myeloproliferative neoplasms.

Introduction: Dickkopf-3 (Dkk3) has been proposed as tumor suppressor gene and a marker for tumor blood vessels and has pro-angiogenic properties. Dkk3 is expressed in platelets and megakaryocytes from healthy controls and patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN). The aim of this study is, to find out whether patients with MPN have higher Dkk3 serum levels than normal controls. Material & methods: We analyzed Dkk3 serum levels with ELISA in patients with newly diagnosed and untreated MPN, including 10 essential thrombocythemia (ET), 10 polycythemia vera (PV), 10 primary meylofibrosis (PMF) and 10 healthy blood donors and correlated these findings with biological and clinical key data and the JAK2-V617F status. Dkk3 levels were corrected to platelet count, Dkk3c, as patients with MPN have higher platelet counts than controls. Results: As expected, patients with MPN have higher platelet counts than normal controls. Dkk3 serum levels of patients with MPN (5.4 +/- 6.1 ng/ml) showed no significant difference compared to normal controls (4.4 +/- 3.8 ng/ml). Regarding Dkk3c, a significant difference to controls was found in PV (8.5 +/- 8.7 ng/ml; p = 0.04), but not in ET and PMF (5.7 +/- 3.8 ng/ml; p = 0.07 and 2.7 +/- 3.6 ng/ml; p = 0.9; respectively. Dkk3c correlated with the JAK2-V617F mutational burden (p = 0.014, Rho = 0.445). Conclusion: Dkk3 levels corrected to platelet count showed higher levels in PV than normal controls. Elevated Dkk3c level could possibly correlate to platelet activation in PV patients and increased Dkk3 release. Whether this remains a surrogate marker of platelet release or it contributes to the thrombophilic state through its pro-angiogenic properties remains to be shown. (C) 2013 Elsevier Ltd. All rights reserved.